State of Michigan Retirement System Acquires 678,600 Shares of Hims & Hers Health, Inc. $HIMS

State of Michigan Retirement System lifted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 49.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,057,700 shares of the company’s stock after purchasing an additional 678,600 shares during the period. Hims & Hers Health comprises about 0.6% of State of Michigan Retirement System’s investment portfolio, making the stock its 27th largest position. State of Michigan Retirement System owned 0.91% of Hims & Hers Health worth $116,713,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in HIMS. Invesco Ltd. boosted its position in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after buying an additional 2,128,587 shares during the period. Clear Street LLC bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $83,582,000. Norges Bank purchased a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $78,464,000. Marex Group plc bought a new position in Hims & Hers Health in the second quarter worth approximately $53,626,000. Finally, Man Group plc grew its stake in Hims & Hers Health by 345.9% in the second quarter. Man Group plc now owns 816,582 shares of the company’s stock worth $40,707,000 after purchasing an additional 633,432 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 131,974 shares of company stock valued at $4,763,800. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Down 2.0%

NYSE:HIMS opened at $23.02 on Friday. The company’s 50-day simple moving average is $32.96 and its 200-day simple moving average is $43.47. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a fifty-two week low of $21.12 and a fifty-two week high of $72.98. The stock has a market capitalization of $5.24 billion, a P/E ratio of 42.63, a P/E/G ratio of 3.87 and a beta of 2.43.

Hims & Hers Health declared that its Board of Directors has initiated a stock repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HIMS. BTIG Research decreased their target price on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Zacks Research downgraded Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Barclays assumed coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 target price on the stock. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $42.62.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS is expanding its care stack by adding multicancer screening (Grail’s Galleri) to its platform, which can increase revenue per patient and strengthen its diagnostics-to-care ecosystem. Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
• Positive Sentiment: Analysts note HIMS is scaling a platform-led digital healthcare model (Labs, AI, YourBio Health) that could lift margins and stickiness if execution continues. Hims & Hers Strengthens Platform-Led Digital Healthcare Model
• Neutral Sentiment: Market response has been volatile: initial share gains after the $49 semaglutide reveal were followed by declines as legal and regulatory reactions emerged; expect elevated volume and short-term price swings. Hims’ $49 weight-loss pill rattles investor case for cash-pay obesity market
• Negative Sentiment: Novo Nordisk has publicly accused HIMS of illegal mass compounding and has vowed legal action, creating litigation risk, potential injunctions, and reputation/partnership fallout. Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version
• Negative Sentiment: The FDA’s leadership signaled potential enforcement against mass-marketed copycat drugs, raising regulatory risk that could limit HIMS’s ability to sell compounded GLP‑1s at scale. FDA’s Makary pledges crackdown on mass marketing of ‘illegal copycat drugs’
• Negative Sentiment: Broader market impact: major pharma peers (Novo, Eli Lilly) saw share moves tied to the story, and investors are weighing potential costly legal fights, regulatory scrutiny, and patient-safety scrutiny that could blunt near-term revenue from the pill initiative. Hims & Hers falls after Novo’s legal threat

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.